Areteia Therapeutics last raised $425.0M in its Early Stage VC (Series A1) (Feb 2024).
- ·The complete investor list: 11 names
- ·Watch Areteia Therapeutics: the Monday email on marks, rounds and moves
Areteia Therapeutics funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Feb 2024 | Early Stage VC (Series A1) | $425.0M | ▮ | ▮ |
| Jun 2022 | Later Stage VC | $360.0M | ▮ | ▮ |
Membership and data by Private Market View
Areteia Therapeutics valuation
Areteia Therapeutics's last known valuation is $1.3 billion, from Feb 2024. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Areteia Therapeutics raised?
Areteia Therapeutics has raised $425 million across 2 recorded rounds since 2022. The largest was a $425 million Series A1 in Feb 2024.
Areteia Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently in Feb 2025 ($360 million sold to 16 investors).
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Encoded Therapeutics ($1.8 billion), Formation Bio ($1.7 billion) and Neurona Therapeutics ($1.1 billion).
How Areteia Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Areteia Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked about Areteia Therapeutics
- What is Areteia Therapeutics worth?
- Areteia Therapeutics's last known valuation is $1.3B.
- How much has Areteia Therapeutics raised?
- Areteia Therapeutics has raised $425.0M in total funding across 2 recorded rounds.
- When did Areteia Therapeutics last raise?
- Areteia Therapeutics last raised in Feb 2024 (Early Stage VC (Series A1)), raising $425.0M.